New drug combo shows promise for Hard-to-Treat prostate cancer
NCT ID NCT04019327
First seen Nov 05, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The treatment is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lehigh Valley Health Network (Data Collection Only)
Allentown, Pennsylvania, 18103, United States
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Limited protocol activity)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.